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Major depression is a serious psychiatric illness that has continued to increase in 
prevalence. In 2017, an estimated 11 million U.S. adults aged 18 or older had at least 
one major depressive episode with severe impairment.1 According to the Centers for 
Disease Control, depression is addressed in 9.3% physician office visits and 10% of 
emergency room visits.2 The management of major depression not only impacts the 
healthcare system but also poses an economic burden as it costs the US $210.5 billion 
per year.3 The most common form of treatment for major depressive disorder has been 
oral antidepressants. These drugs treat depression through mechanism of targeting the 
central neurotransmitter system, primarily serotonergic, noradrenergic and 
dopaminergic pathways and have been successful in managing depressive symptoms 
in many patients. Approximately 30% of individuals continue to suffer from major 
depression despite one or more adequate trials of antidepressants, thus identifying 
these patients with a diagnosis of Treatment-Resistant Depression (TRD).4,5,6,7 Patients 
with TRD experience increased chronicity of depression, functional disability, and 
overall morbidity, resulting in greater therapeutic challenges.4  
 Over the last few years, ketamine has been studied as a possible treatment 
option for Major Depressive Disorder (MDD)a and TRD. Ketamine is an NMDA receptor 
antagonist that targets the glutaminergic system and produces rapid antidepressant 
effects from mechanisms that are still incompletely defined.5 In March 2019, the FDA 
approved intranasal esketamine, an enantiomer of ketamine, as a treatment for those 
who have failed at least two antidepressant medications.6The approval of esketamine 





breakthrough in psychiatric medicine and provides promise for the future of depression 
management. Nonetheless, the effects from treating TRD with ketamine are not fully 
characterized or known. For that reason, identifying patients and other factors 
associated with an increased likelihood of success with esketamine would not only 
expand the knowledge base, but also limit potential adverse effects from treating 
persons who are not likely to benefit. These factors might include age, symptom 
severity, comorbid psychiatric disorders, route of drug administration, drug formulation 
et cetera. Moreover, examining the different TRD patient populations who experience 
benefits from esketamine/ketamine therapy would aid in determining who are most likely 
to benefit from it.  
DISCUSSION: 
To date, research on ketamine’s effects on MDD has included only adult 
participants most of whom ranged in age from 18-64 years.4,5 Fortuitously, ketamine 
has been studied in both men and women who failed previous antidepressant 
medications. Otherwise investigations focused on different populations of depressed 
patients and monitored different outcomes.  
Suicidal ideation in major depression can increase the risk of mortality MDD 
alone causes disability.  A double-blind, placebo-controlled trial by Ionescu et al. 
explored the short and long-term antidepressant efficacy of repeated dose (0.5mg/kg) 
IV ketamine in comparison with placebo in medicated, TRD outpatients with chronic 
suicidal ideation.6  The participants included 24 adults of both sexes between ages of 
18-65 years-old with MDD as their primary diagnosis and with distressing suicidal 





excluded from this outpatient study. Other exclusion criteria included a diagnosis of 
bipolar depression, current pregnancy, unstable medical illness, psychotic features, a 
history of multiple adverse drug reactions, any history of substance use disorder, a 
positive urine toxicology screen, and any history of recreational ketamine abuse. 
Participants completed three initial visits prior to ketamine treatment (pre-infusion 
phase) and received a total of six 45- minute infusions of IV ketamine or placebo over 
the course of three weeks (active phase). They were followed every other week for an 
additional three months following the active phase of the trial (follow-up phase). The 
primary outcome was depression experienced over the past week as rated by the 
Hamilton Rating Scale for Depression (HRSD or HAM-D).b A positive response was 
defined as a 50% or greater improvement in the HRSD score. An HRSD score of 7 or 
less met criteria for remission of depression.  The presence of suicidal ideation (SI) was 
the secondary outcome and was assessed by Columbia Suicide Severity Rating Scale 
(C-SSRS)c score based on a five- point scale with “0” being the absence of SI. Overall, 
depression decreased significantly across infusions, whereas SI did not.6 During the 
active phase, 25% of the subjects in the ketamine group and 35% subjects in the 
placebo group experienced antidepressant responses. When examining remission 
rates, 17% of the ketamine subjects met criteria for remission while only 8% did so in 
the placebo group. During the follow up phase, 22% of the ketamine group met criteria 
for antidepressant response and remission, while 27% of placebo subjects had an 
antidepressant response and 18% met criteria for remission. The was no significant 
difference between responders or remitters between the placebo and ketamine groups.6  





ketamine infusion, four of these subjects continued to experience lack of SI in the 
beginning of the follow-up phase; however, only one subject maintained absence of SI 
at the end of the three month follow up phase. Among the placebo group, two patients 
met criteria for absence of SI at the end of the follow- up phase. In conclusion, IV 
ketamine infusions did not outperform placebo in terms of short or long-term 
antidepressant and anti-suicidal efficacy.6 Nonetheless, participants in the study 
reported decreased suicidal ideation within hours of administration of ketamine, 
suggesting its effects may be transient and dose dependent. Several limitations to this 
study as well as significant strengths may have influenced the outcomes. The first 
limitation was a small sample size due to difficulty with recruitment and retention of 
participants as only 14 of the 26 participants completed the study. The low retention of 
participants was due to the lack of compensation and the unfounded (or unrealistic) 
expectation that severely depressed patients would be able to comply with extended 
research.6 The small sample size may have affected the evaluation of true differences 
between the groups.6 Secondly, the participants were maintained on their other 
psychiatric medications during the infusion phase of the study; thus any effects due to 
those medications could not be distinguished from effects due to ketamine. Third, the 
study was conducted with outpatient participants only and excluded those with acute SI 
who met criteria for hospital admission. The inclusion of only outpatient participants may 
have contributed to a lack of significant difference in depression and SI pre-and post-
infusion with ketamine since the participants’ baseline SIs were already low.6 Lastly, no 
24-48-hour post-infusion evaluation was performed. The short duration of the four-hour 





ketamine.6 Strengths of the study included the inclusion of participants with TRD 
experiencing both chronic and current SI, the double-blind placebo controlled trial study 
design, and extended three month follow up phase which observed the prolonged 
effectiveness of ketamine.6 
A review of clinical trials by Kraus et al. investigated the efficacy and tolerability 
of ketamine in patients with unipolar or bipolar MDD (as defined by DSM criteria), a 
population that was excluded in the above trial. This review included meta-analyses and 
Cochrane reviews from peer-reviewed journals and excluded trials with individuals who 
had other primary psychiatric diagnoses.8 The outcome of depression was assessed 
solely with rating scales, including the HAM-D/HRSD, Montgomery-Asberg Rating Scale 
(MADRS)d, and Beck Inventory (BDI).e The antidepressant effects were evaluated at 24 
hours post ketamine treatment in most of the studies for which reason it was chosen as 
the main outcome. This review included a total of 12 clinical trials that had participants 
with unipolar MDD as the primary diagnosis and 7 clinical trials that had participants 
with bipolar MDD as the primary diagnosis for a total sample size of 226 participants .8 
Studies using either intranasal (IN) or IV ketamine infusions were included. Significant 
response was defined as reduction in baseline depression scores in all studies of 50% 
or higher.8 Twenty-four hours post-treatment, ketamine, without exception, was superior 
to placebo as evidenced by a significant response rate of 59%. Specifically, depression 
rating scores decreased in the ketamine treatment groups an average of 10.91 in HAM-
D/HDRS scores, 15.7 in BDI scores, and 20.8 in MADRS scores.9 Overall the most 
significant antidepressant affects were noted on the first day of ketamine treatment with 





were highly effective at producing rapid antidepressant effects in patients with bipolar 
and unipolar MDD.  Response rates up to 88% after the first 24 hours of ketamine 
treatment were observed with an average duration of 1-2 weeks.8 Relapse rates after 
treatment with ketamine were high and up to 90% in some trials.  The latter findings 
exposed the transient effects of ketamine and hence, the need for further research on 
means to prolong its antidepressant effects. Nonetheless, ketamine may be a potentially 
useful in the acute suicidal crises and highly resistant depression.8 Furthermore, an 
individual’s initial response to ketamine may be an indicator of further responses.8 Study 
limitations were the inclusion of clinical trials utilizing different IV doses of ketamine thus 
lacking the a uniform dose regimen among all trials. An additional limitation was the 
inclusion of trials that used ketamine as an add-on treatment to medication, ECT, et. 
cetera for depression as well as trials where ketamine was used as the primary 
treatment. A strength was the large sample size of 12 clinical trials. Additionally, all the 
trials used scores from standardized depression rating scales as instruments for the 
measuring primary outcomes.  
 Besides population, another factor for choosing successful outcomes with this 
therapy might include the presence or absence of ketamine-induced dissociative 
symptoms as predictors of ketamine’s antidepressant efficacy. A secondary study by 
Niciu et al. investigated whether an increase in dissociative symptoms after initial 
ketamine treatment would predict improvement in depressive symptom scores.9 
Findings from three trials that included adult participants ages 18-65 years, 84 with 
MDD and 42 with bipolar depression (BD) were analyzed in this study.f Prior to 





psychotic features for a duration of at least two weeks. Individuals with MDD were 
medication-free for at least two weeks prior to the first ketamine or placebo infusion and 
persons with BD were maintained on lithium or valproate. The HAM-D scale was used 
to measure antidepressant response and Clinician Administered Dissociative States 
Scale (CADSS) was used to evaluate dissociation effects. Both scores were calculated 
at 60 minutes prior to infusion and 40 minutes post-infusion. The CADSS scale was 
further characterized into different subscales such as derealization, depersonalization, 
and amnesia.9  A significant association between depersonalization symptoms and 
greater antidepressant responses across all time points and studies, suggested that 
depersonalization effects may be the best predictor antidepressant response in 
individuals treated with ketamine.9   Study limitations were the inclusion of participants 
with bipolar depression and major depressive disorder and possible type 1 error 
because the study was a secondary analysis.9  
ROUTE OF ADMINISTRATION: 
 In the last 10 years, many studies examined the use of intravenous ketamine for 
TRD. More recent studies have examined intranasal esketamine. The only FDA 
approved use of ketamine in the treatment of depression is the intranasal form, 
esketamine, approved in March 2019.4 Although more research on intravenous 
ketamine compared with intranasal esketamine is available, obstacles to the IV route 
remain. For example, a universal induction and tapering dose for IV ketamine has yet to 
be determined. Additionally, the IV route for ketamine is not acceptable for all patients 
because they are either unwilling to receive IV treatment or cannot tolerate it for other 





tolerability, and ease of administration. Intranasal ketamine can be administered in an 
outpatient setting; nonetheless, patients need to be monitored by a physician for 1-2 
hours following administration.  The potential for abuse of either form of this drug is 
obviated somewhat by the need for clinical supervision of dosing. 
RECOMMENDATIONS FOR FURTHER RESEARCH: 
Ketamine and esketamine have evidence for efficacy in the treatment of severe 
major depressive disorders; rapid antidepressant effects occur within 24 hours of 
administration.7,10 Further research is necessary to determine how much ketamine or 
esketamine would provide an effective dose for severe depression and what doses 
would be standard treatment. Additionally, the efficacy of ketamine/esketamine in 
conjunction with other treatment modalities such as electroconvulsive therapy, cognitive 
behavioral therapy, or pharmacotherapy should be explored. Lastly, the long-term side 
effects of ketamine and esketamine are unknown because research follow-up has been 
relatively short in duration.11 
CONCLUSION: 
Severe depression is a crippling disorder that plagues the lives of many people 
and negatively effects mental and physical well-being. The introduction of TRD 
treatment with ketamine, which works by a different mechanism of action compared to 
traditional antidepressants, has provided an alternative for these patients. A rapid 
decrease in depressive symptoms occurs within hours after treatment with ketamine. 
The total duration of antidepressant effects is transient and is still open for further 





depression should not be overlooked due to its transient nature, as it may have potential 
for treatment in critical situations.  Furthermore, the rapid onset of the antidepressant 
effects of ketamine may provide effective treatment for acute severe depression which 
may present in emergency settings. In addition, ketamine’s antidepressant effects have 
been demonstrated in adults with a primary diagnosis of MDD, specifically TRD. It is 
also effective in bipolar disorders with depression. More information is needed about the 
long-term effects of ketamine therapy. Nonetheless, ketamine and esketamine are 
potential treatments for individuals with severe depression who have failed one or more 
traditional antidepressant medications.  
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a Major Depressive Disorder (MDD) Criteria- at least 5 of the following symptoms have to be present during the 
same 2-week period (and at least 1 of the symptoms must be diminished interest/pleasure or depressed mood): 
depressed mood, diminished interest  or loss of pleasure in almost all activities (anhedonia), significant weight 
change or appetite disturbance, sleep disturbance, psychomotor agitation or retardation, fatigue or loss of energy, 
feelings of worthlessness, diminished ability to think or concentrate; indecisiveness, recurrent thoughts of death, 
recurrent suicidal ideation without specific plan, or suicide attempt or specific plan for committing suicide. 
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, 
DC: American Psychiatric Association; 2013.  
b Hamilton Rating Scale for Depression (HRSD/HAM-D)- Stratifies the severity of depression based on depressed 
mood, feelings of guilt, suicide, insomnia, work/interests, retardation, agitation, psychiatric anxiety, somatic 
anxiety, GI somatic symptoms, general somatic symptoms, genital symptoms, hypochondriasis, weight loss, and 
insight. The original HAM-D has 21 items, but scoring is based on only the first 17. Hamilton, M. A rating scale for 
depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56–62. doi:10.1136/jnnp.23.1.56 
c Columbia-Suicide Severity Rating Scale (C-SSRS)- screens for suicidal ideation and behavior. Posner K, Brown GK, 
Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from 
three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266–1277. 
doi:10.1176/appi.ajp.2011.10111704 
d Montgomery Asberg Rating Scale (MADRS)-stratifies severity of depressive episodes in adults based on apparent 
sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulty, lassitude, 
inability to feel, pessimistic thoughts and suicidal thoughts. Montgomery, S., & Åsberg, M. (1979). A New 





                                                                                                                                                                                               
Depression Scale Designed to be Sensitive to Change. British Journal of Psychiatry, 134(4), 382-389. 
doi:10.1192/bjp.134.4.382 
e Beck Inventory (BDI)- 21-item, self-report rating inventory that measures characteristic attitudes and symptoms 
of depression. https://www.apa.org/pi/about/publications/caregivers/practice-settings/assessment/tools/beck-
depression. 
f Bipolar Depression- a mental illness characterized by periods of deep, prolonged and profound depression that 
alternate with periods of an excessively elevated or irritable mood known as mania. American Psychiatric 
Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, DC: American 
Psychiatric Association; 2013. 
